The occurrence timeline of steroid-induced ocular hypertension and cataract in children with systemic autoimmune diseases

Honggai Yan · Xiaohua Tan · Jifeng Yu · Tianwei Liang · Wei Shi · Li Li · Chunxia Peng

Received: 10 August 2021 / Accepted: 3 January 2022 / Published online: 19 January 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract
Purpose Steroid-induced ocular hypertension (SIOH) and cataract can result in visual loss. This study evaluated the timetable of SIOH and steroid-induced posterior subcapsular cataract (SI-PSC) occurrences in children with systemic autoimmune diseases (SAD) undergoing long-term systemic corticosteroid treatment.

Methods Thirty-seven children with SAD treated with long-term oral corticosteroids were enrolled in this study. Intraocular pressure (IOP), SI-PSC occurrences, visual field and peripapillary retinal nerve fibre layer (pRNFL) thicknesses were recorded every 3 months for at least 6 months.

Results Of the 37 children, with average age 11.0 ± 2.9 years, 22 patients (59.5%) had SIOH, 2 progressed as glaucoma at the 18-month and 3-year follow-up, respectively, and 12 (32.4%) patients had SI-PSC. Among patients with SIOH, 45.5% (10/22) of them had SI-PSC occurrence, and among patients with normal IOP, 13.3% (2/15) of them had SI-PSC. Seventeen patients participated in a longitudinal study with a follow-up period of at least 18 months. The incidence of SIOH started at 1 month 52.9% (9/17) and gradually increased to 70.6% (12/17) at 6 months, then decreased to 35.3% (6/17). SI-PSC onset started at 6 months (17.6%, 3/17), and its occurrence increased to 35.3% (6/17) at 12 months and reached to 41.2% (7/17) at 18 months. The pRNFL was thicker in the children with SIOH than the healthy controls (p = 0.01).

Conclusion SIOH and SI-PSC are common coexistent complications in children with long-term corticosteroids treatment, and the occurrence time is during the first month and 6 months, respectively. Patients with SIOH have a higher probability of cataract.

Keywords Steroid-induced ocular hypertension · Steroid-induced posterior subcapsular cataract · Systemic corticosteroid treatment · Systemic autoimmune disease
Background

Corticosteroids have potent anti-inflammatory and immunosuppressive activities and are usually chosen for treating autoimmune diseases. The adverse events of long-term oral corticosteroids therapy are still a major concern in the management of systemic autoimmune conditions. Steroid-induced ocular hypertension (SIOH) and posterior subcapsular cataract (SI-PSC) are the most common ocular issues, especially in paediatric patients [1].

SIOH is defined as the elevation of intraocular pressure (IOP) due to long-term corticosteroid usage. If long-term ocular hypertension remains unrecognized, it will lead to progressive damage to the optic nerve and induce irreversible visual loss and defect of visual field, which it known as steroid-induced glaucoma. Though patients of any age can get steroid-induced IOP elevation, IOP elevation and visual field damage can be more severe and rapid in children than in adults [2–4]. Young patients have longer remaining life spans than adults. The damage to vision and visual field will have a greater adverse influence on their daily life and cause a significant health burden for society. Thus, more attention should be paid to IOP in children undergoing long-term systemic steroid treatment. The precise mechanism for SIOH is not clear. Study found that steroid-induced changes may occur at the subendothelial region at the inner wall of the schlemm canal, which will cause fibrillary material deposited, then decreased trabecular meshwork outflow [5].

SI-PSC is a subtype of cataracts, and long-term corticosteroids treatment is an established risk factor for its formation [6]. In 1960, Black was the first to report that patients with rheumatoid arthritis who had been treated with long-term general corticosteroid had SI-PSC [7]. The dosage and duration of steroid treatment have been reported to be associated with the degree of PSC [7, 8]. The characteristics of steroid-induced cataracts include PSC, which mostly affects both eyes and progresses slowly. Most cataracts do not have an impact on vision; however, those with impaired vision due to cataracts will undergo cataract surgery. The aetiology of steroid cataract has been found that glucocorticoids may induce changes to the transcription of genes in lens epithelial cells which are related to the cellular processes. It is account for the development of PSC [6]. Children are in a critical period of vision development; a severe cataract impedes the vision development of young patients, resulting in the formation of amblyopia. In children, cataract surgery is also more challenging and there are more complications in this patient group than in adults [9]. Consequently, when children with autoimmune diseases undergo long-term systemic steroid treatment, it is necessary to perform a slit-lamp examination for cataract at every follow-up.

Although both SIOH and SI-PSC are common ocular complications in patients with long-term systemic steroid treatment, there are limited data on the relationship of hypertension and cataracts in children who use oral corticosteroids for a long period of time. Thus, the present study aimed to observe the prevalence and onset time of SIOH and SI-PSC and the timelines of their occurrences and evolution in children undergoing long-term systemic steroid therapy.

Subjects and methods

The prospective and longitudinal study was conducted at the Department of Ophthalmology in Beijing Children’s Hospital, Capital Medical University in China from November 2017 to February 2019, after receiving approval from the institutional ethics committee. The study was conducted in adherence with the tenets of the Helsinki Declaration. Thirty-seven consecutive children with autoimmune diseases diagnosed by senior doctors of the Department of Rheumatology and Immunology in Beijing Children’s Hospital were enrolled. Healthy children with normal best corrected visual acuity (BCVA) and normal IOP (11–21 mmHg) who visited our hospital for physical examinations were enrolled as healthy controls (HCs), and their age and gender were matched to the study group. Written informed consent was obtained from the parents or guardians of each of the study’s subjects.

All the patients had undergone standard long-term systemic steroid treatment in which methylprednisolone was administrated intravenously 10–30 mg/kg/d for 3 days, followed by an oral steroid at a dose of 1–2 mg/kg/d for 2–4 weeks, and tapered by 5 mg/w until the minimal required dose (5 mg) to prevent remission. Patients with a family history of glaucoma and ocular diseases or ocular surgeries, with a follow-up time less than 6 months and who did not regularly use steroids, were excluded from the study. Among the 37 cases with at least 6 months of follow-up, 17
patients who completed more than 18 months of follow-up were enrolled in the longitudinal study group.

Ophthalmologic examinations

Each patient underwent a BCVA test with the Snellen chart, anterior and posterior segment evaluation by slit-lamp microscopy and indirect ophthalmoscopy. PSC was evaluated by slit-lamp microscopy. Visual field was detected by Octopus automated perimetry (OCTOPUS 900, EyeSuite Static perimetry, V3.6.1, HAAG-STREIT, Switzerland) for the patients older than 5 years of age.

IOP measurement and cataract evaluation

IOP was measured by an iCare rebound tonometer (Icare Finland, Oy) 6 times, and the average values were recorded to avoid variations. Ocular hypertension was defined as IOP > 21 mmHg or an IOP increase of > 6 mmHg in comparison with IOP before steroid treatment. Patients with IOP > 21 mmHg were given medication to control IOP. It usually begins with a beta-blocker, followed by carbonic anhydrase inhibitors and topical prostaglandins to control the pressure. IOP is closely monitored every week until it is normal. In our study, IOP was measured in all the patients before steroid treatment and monitored once a week in the first month and 2 weeks thereafter. The IOP values and the number of anti-glaucoma eye drops that were administered were recorded every 3 months and an index was used to evaluate the degree of IOP for at least 6 months. Cataract was evaluated by slit-lamp microscopy examination to observe the posterior subcapsular lens opacities. The degree of opacity was classified into 4 groups by Crews [10]: (1) occasional subcapsular opacities or vacuoles in central region with or without polychromatic lustre and distortion of specular reflex; (2) small clusters of subcapsular opacities remaining discrete; (3) multiple clusters of subcapsular opacities which had mainly coalesced; and (4) extensive subcapsular opacities forming a plaque on the back of the lens and extending forwards into the cortex. Every 3 months, the patients underwent a lens examination to determine the occurrence of PSC.

Optical coherence tomography (OCT) examinations

The results of visual field testing for children are less reliable due to poor patient cooperation. Changes in the peripapillary retinal nerve fibre layer (pRNFL) thickness were detected using the Heidelberg Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) machine according to the standard protocols to monitor glaucomatous onset and progression. All the OCT examinations were performed by the same, experienced ophthalmologist.

Statistical analyses

Statistical analysis was performed using a statistical software package (SPSS, version 16.0; IBM Corp, Armonk, NY, USA). Frequency and descriptive statistics were used for the data analysis. Demographic and clinical characteristics, including age and pRNFL, were compared using independent sample t tests. Sex and the cataracts in patients with SIOH hypertension and normal IOP were compared using the Chi-squared test, and the variables were tested for normality at the same time. The results are presented as means ± standard deviation (SD). A p value < 0.05 was considered statistically significant.

Results

Demographic and clinical features

A total of 56 children were enrolled in this study. Nineteen patients were excluded, including 9 patients who did not use steroids regularly, 7 patients that had used steroids for less than 6 months, 2 patients with a history of eye trauma and 1 patient with optic disc swelling (Fig. 1). Thus, a total of 37 patients were included; of these, 12 were boys and 25 were girls. Their ages ranged from 5 to 16 years (mean ± SD: 11.0 ± 2.9 years). Of the 37 patients, 34 had BCVA greater than or equal to 0.8. Two patients had BCVA between 0.6 and 0.7 because of cataract. Only one patient had glaucoma of the left eye, the vision of the right eye was 1.0, and the left eye was light perception.

Seventeen patients had a follow-up time of more than 18 months and were assigned to the longitudinal study group, with ages ranging from 7 to 16 years (mean ±
SD: 11.3 ± 2.6 years). They mainly suffered from systemic lupus erythematosus, allergic purpura, dermatomyositis and rheumatoid arthritis. There were 22 patients (59.5%) with SIOH and 12 patients (32.4%) with SI-PSC. All but one of the ocular hypertension patients had binocular hypertension. Two of these patients had visual field damage and were diagnosed with steroid-induced glaucoma. Due to the general condition of the two patients, they still needed systemic steroids treatment. So anti-glaucoma surgery was adopted for the two patients. One girl of the two patients had ocular hypertension and visual field damage in one eye after undergoing steroid treatment for 3 years. The cataracts were bilateral in all but one of the patients. All the demographic and clinical features are listed in Table 1.

IOP alterations and cataract occurrences with time

The incidence of ocular hypertension and cataracts in all the study patients is presented in Fig. 2. In the patients with SIOH, 10 patients got cataracts (45.5%) and 12 did not. In the patients with normal IOP, 2 got cataracts (13.3%), 13 did not. The incidence of cataract was much higher in the patients with an elevated IOP than in the patients with normal IOP; however, the difference was not statistically significant (p = 0.07). One special case was about a 16-year-old girl who was diagnosed with systemic lupus erythematosus (SLE) and treated with oral steroids for 3 years. When she came to the hospital for the pain and low vision of the left eye, IOP showed 18 mmHg of the right eye and 57 mmHg of the left eye. The C/D of the right eye was 0.2, and the C/D of the left eye was 0.9. OCT examination showed RNFL was severely

Fig. 1 Algorithm of the included children

Fig. 2 The incidence of steroid-induced ocular hypertension and cataract in enrolled all subjects

Int Ophthalmol (2022) 42:2175–2184
thinner of the left eye. She was diagnosed with one eye glaucoma, and the other eye was normal (Fig. 3).

There were 17 patients whose regular follow-up data were collected every 3 months for more than 1.5 years. The basic data are presented in Table 1; the total anti-glaucoma eye drops and SI-PSC situations are presented in Table 2. The timeline of the number of anti-glaucoma eye drops and cataract occurrence is shown in Fig. 4. Nine (52.9%) of the patients with ocular hypertension appeared within the first month after steroid treatment. Its incidence gradually increased to 70.6% (12/17) in 6 months, and then, it decreased to 35.3% (6/17) in 18 months. The degree of ocular hypertension was reflected by the number of anti-glaucoma medicines administered, beginning with 21 counts for 1 month, increasing to 22 counts at 3 months and reaching its peak of 24 counts at 6 months. It then gradually decreased to 13 counts at 18 months.

The earliest occurrence of SI-PSC was 6 months after steroid treatment, and the onset time for most of the cataracts (6/7) occurred from 6 months to 1.5 years. All but one of the patients who acquired SI-PSC got SIOH. None of the 17 patients had progressed glaucoma or suffered visual field and optic nerve damage.

Fig. 3 The fundus of a 16-year-old girl with SLE who was diagnosed as steroid-induced glaucoma of the left eye after treated with oral steroid for 3 years. The C/D of the right eye was 0.2 and the left eye was 0.9

Fig. 4 The timeline of the number of anti-glaucoma eye drops and cataract occurrence

Optic nerve alterations detected by OCT

We compared the pRNFL between the patients with SIOH and the HCs (Table 3). Seven regions were analysed and compared, including RNFL-G T TS TI N NS and NI. There were no significant differences in the pRNFL thickness ($p > 0.05$) between the two groups except for the RNFL-NI region (control group $102.0 \pm 19.8$ um, study group $109.8 \pm 22.4$, $p = 0.01$). We compared the pRNFL between the eyes with hypertension and the HC group and found that the pRNFL was thicker in the G, TS, N, NI regions of the eyes with hypertension ($p = 0.01$, 0.03, 0.02, 0.00, respectively). No significant difference was found in the pRNFL between the patients with normal IOP and the HCs.

Discussion

We performed a detail analysis of children with systemic autoimmune diseases who had undergone treatment with oral steroids for more than 6 months. We found that ocular hypertension and cataracts are the most common ocular complications and the patients with ocular hypertension had a higher percentage of cataracts than the patients with normal
IOP. We also found that the pRNFL was thicker in patients with SIOH than the HC group. In this study, 59.5% of the patients got ocular hypertension. Previous studies have reported that children are considered to be particularly susceptible to developing SIOH [11, 12]. Kwok et al. found that ocular hypertension occurs more frequently, more severely and more rapidly in children than in adults using topical dexamethasone [13]. Systemic steroids can also be considered to cause significant, but asymptomatic, ocular hypertension in paediatric patients [14, 15]. Grossman [16] reported on 1133 children treated with a systemic steroid and found that 37% of the patients developed elevated IOP. Because oral steroids and topical steroids elevate IOP in different ways, Savleen Kaur reported that the elevation of IOP was lower and was controlled with fewer doses of drugs in patients receiving oral steroids in comparison with patients using topical steroids [17]. A majority of studies have reported that IOP increases 3–6 weeks after the beginning of topical steroid use, and some IOP hypertension can be found as early as the first or second week [2, 18–20]. Prasad found that increased IOP occurred in 61% of patients in the first month and in 87.9% of patients in the first 6 months of systemic steroid treatment [21].

In our study, the earliest response happened during the first week, and most of the patients got ocular hypertension during the first year. In half of the patients with ocular hypertension, elevated IOP appeared within the first 6 months. The number of new patients with ocular hypertension decreased gradually with the extension of the duration of steroid use and the number of anti-glaucoma medications decreased. Chen reported that the IOP can return to baseline once the use of corticosteroids is terminated [22]. We consider that as the steroid dose is decreased, the IOP can gradually return to normal and fewer number of patients will have ocular hypertension. The pathophysiology of SIOH is such that the steroids act

### Table 1 Demographic and clinical features of the study participants

| Variables                                    | Total patients | Longitudinal follow-up patients | Healthy controls (HCs) | P value |
|----------------------------------------------|----------------|---------------------------------|------------------------|---------|
| Subjects                                     | 37             | 17                              | 68                     |         |
| Age (mean ± SD), y                           | 11.0 ± 2.9 (5–16) | 11.3 ± 2.6 (7–16) | 10.4 ± 2.2 (6–16) | 0.25    |
| Gender (M/F)                                 | 12/25          | 8/9                             | 29/39                  | 0.30    |
| Autoimmunity disorders (%), n                |                |                                 |                        |         |
| Systemic lupus erythematosus (SLE)           | 18 (48.6)      | 8 (47.1)                        |                        |         |
| Dermatomyositis                              | 9 (24.3)       | 7 (41.2)                        |                        |         |
| Rheumatoid arthritis                        | 4 (10.8)       | 0 (0)                           |                        |         |
| Others                                       | 6 (16.2)       | 2 (11.8)                        |                        |         |
| Term of steroid treatment (mean ± SD) Range  | 18.8 ± 9.8 (6–40) | 21.4 ± 5.2 (18–30) | –                     | –       |
| Steroid-induced ocular hypertension, n       | 22 (59.5%)     | 12 (70.6%)                      | –                      | –       |
| Steroid-induced glaucoma, n                 | 2 (5.4%)       | 0                               | –                      | –       |
| Steroid-induced cataract                     | 12 (32.4%)     | 7 (41.2%)                       | –                      | –       |
| Best corrected visual acuity, n             |                |                                 | 68                     |         |
| 0.8–1.0                                      | 34             | 16                              |                        |         |
| 0.6–0.7                                      | 2              | 1                               |                        |         |
| Light perception                             | 1              | 0                               |                        |         |
| Intraocular pressure (mean ± SD), mmHg      |                |                                 |                        |         |
| Right eye                                    | 18.0 ± 2.9     | 17.1 ± 2.5                      | 15.5 ± 3.0             |         |
| Left eye                                     | 18.3 ± 3.4     | 17.4 ± 3.3                      | 15.8 ± 3.2             |         |
| Patient no | 1 m          |          | 3 m          |          | 6 m          |          | 9 m          |          | 12 m         |          | 15 m         |          | 18 m         |          |
|------------|--------------|----------|--------------|----------|--------------|----------|--------------|----------|--------------|----------|--------------|----------|--------------|----------|
|            | Drugs | Cataract | Drugs | Cataract | Drugs | Cataract | Drugs | Cataract | Drugs | Cataract | Drugs | Cataract | Drugs | Cataract |
| 1          | 0     | –        | 0     | –        | 1     | –        | 1     | –        | 0     | –        | 0     | –        | 0     | –        |
| 2          | 2     | –        | 2     | –        | 3     | –        | 2     | –        | 2     | +        | 2     | +        | 0     | +        |
| 3          | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        |
| 4          | 2     | –        | 2     | –        | 3     | –        | 3     | –        | 4     | –        | 4     | –        | 4     | +        |
| 5          | 2     | –        | 3     | –        | 1     | –        | 1     | –        | 0     | +        | 0     | +        | 0     | +        |
| 6          | 1     | –        | 1     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        |
| 7          | 4     | –        | 2     | –        | 1     | +        | 0     | +        | 0     | +        | 0     | +        | 0     | +        |
| 8          | 0     | –        | 3     | –        | 3     | –        | 2     | –        | 2     | –        | 2     | –        | 2     | –        |
| 9          | 0     | –        | 0     | –        | 2     | –        | 2     | –        | 2     | +        | 2     | +        | 2     | +        |
| 10         | 1     | –        | 1     | –        | 2     | +        | 2     | +        | 2     | +        | 2     | +        | 2     | +        |
| 11         | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        |
| 12         | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        |
| 13         | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        | 0     | –        |
| 14         | 3     | –        | 3     | –        | 3     | +        | 3     | +        | 2     | +        | 2     | +        | 1     | +        |
| 15         | 3     | –        | 1     | –        | 1     | –        | 1     | –        | 0     | –        | 0     | –        | 0     | –        |
| 16         | 0     | –        | 2     | –        | 2     | –        | 1     | –        | 1     | –        | 0     | –        | 0     | –        |
| 17         | 3     | –        | 2     | –        | 2     | –        | 2     | –        | 2     | –        | 2     | –        | 2     | –        |
| Total      | 21    | 0        | 22    | 0        | 24    | 3        | 20    | 3        | 17    | 6        | 16    | 6        | 13    | 7        |
| Counts     | 9     | –        | 11    | –        | 12    | 3        | 11    | 12       | 8     | 6        | 7     | 6        | 6     | 7        |
| (n, %)     | 52.9% |          | 64.7% |          | 70.6% |          | 17.6% |          | 64.7% |          | 70.6% |          | 47.1% |          | 35.3% |          | 41.2% |          | 35.3% |          | 35.3% |          | 41.2% |          |
on the glucocorticoid receptors on the trabecular meshwork, induce decreased cellularity of the trabecular meshwork and increase extracellular matrix deposition; this blocks the outflow of aqueous humour and increases IOP [23].

There were 32.4% of the patients got PSC. Kaye [24] and Hayasaka [25] reported that 30% and 33.3% of the patients in their study got PSC after long-term oral prednisone therapy. The prevalence of cataracts was similar to that reports. Some studies have claimed that the incidence of PSC was influenced by the medication dose and the duration of the cataracts; a higher total steroid dose and a longer time could induce a higher incidence of cataracts [25, 26]. In our study, the earliest onset time of cataracts was 6 months after steroid treatment and most of the cataracts happened over the course of 1–1.5 years. It demonstrates that the occurrence of cataracts is dependent on the duration of the steroid therapy; thus, the longer the treatment time, the greater the possibility of developing cataracts. Loredo et al. reported that two patients got cataracts within the first year of steroid treatment [27]. Bachmann found that two children with nephrotic syndrome (NS) developed PSC after 7 and 8 months of steroid treatment [28]. The mechanism of SI-PSC is unknown, and there is no effective treatment except for removal of the cataracts if vision is significantly decreased [6, 29]. In this study, 2 patients’ vision was slightly affected by cataracts, and the vision impairment did not affect their life and Urban et al. reported that visual impairment was rare in the PSC induced by corticosteroid use [30]. However, if cataract seriously affects the patient’s vision, surgery is the best choice.

In our study, the incidence of cataracts was higher in the patients with ocular hypertension than in the patients with normal IOP (45.5% vs. 13.3%, $p = 0.07$). Moreover, all but one of the patients with cataracts got ocular hypertension during the follow-up period. Is there a relationship between steroid-induced IOP hypertension and cataracts? The association between SIOH and SI-PSC has not been reported. A study on 336 patients found that 19 had cataracts caused by long-term oral corticosteroid therapy and 1 had glaucoma attributed to systemic steroid therapy [31]. The patient with glaucoma also had cataracts. The pathogenesis of glucocorticoid-induced cataract is complex. While many theories have been put forward [32], the formation process of PSC cannot be fully

| Table 3 | pRNFL thicknesses in patients’ eyes with intra-ocular hypertension compared with that of normal IOP eyes and HCs eyes |
|---------|----------------------------------------------------------------------------------------------------------------------------------|
| pRNFL thickness (μm) | All patients IOP hypertension eyes | Normal IOP eyes | HCs eyes | P1 all patients versus HCs | P2 hypertension eyes versus HCs | P3 normal eyes versus HCs |
| Global-pRNFL | 103.5 ± 12.0 | 104.9 ± 9.4 | 101.6 ± 15.1 | 104.9 ± 8.9 | 0.07 |
| Temporal | 87.0 ± 15.0 | 85.3 ± 12.6 | 151.4 ± 22.2 | 153.1 ± 17.1 | 0.01 |
| Supero-temporal | 154.7 ± 23.1 | 156.2 ± 17.1 | 154.9 ± 28.3 | 156.7 ± 16.7 | 0.11 |
| Nasal | 60.7 ± 14.6 | 64.3 ± 15.3 | 55.5 ± 11.9 | 58.0 ± 14.5 | 0.32 |
| Supero-nasal | 116.2 ± 23.0 | 117.8 ± 21.7 | 113.8 ± 24.9 | 111.7 ± 22.7 | 0.12 |
| Infero-nasal | 109.8 ± 22.4 | 112.9 ± 20.1 | 105.2 ± 25.0 | 102.0 ± 19.8 | 0.01 |

| 2182 Int Ophthalmol (2022) 42:2175–2184 | Springer |
explained. TGF-β had been proven to be related to the development of posterior capsule transition [33]. Fini et al. stated that excessive TGF-β signalling could lead to ocular hypertension in mouse models [32]. TGF-β signalling for PSC and ocular hypertension is a subject for further research.

One patient in our study got glaucoma after using a low-dose oral steroid for 3 years. This demonstrates that although most of the patients had normal ocular hypertension after their steroid dose is decreased, some patients can still get glaucoma. Thus, IOP should be monitored if a patient is still using steroids.

We found that the pRNFL was thicker in the group of patients with IOP hypertension than in the HC group. This is an interesting finding. We speculate that the observed increase in pRNFL thickness in our patients may reflect an early transient change caused by IOP hypertension. To the best of our knowledge, no previous study has reported a similar result. Aksoy et al. found that there were no statistically significant differences between the ocular hypertension group and the control group [34]. A longer observation time and more subjects are needed to study this further.

This study had several limitations. First, there may have been a bias in choosing the patients because most of our patients were from the Department of Rheumatology and Immunology. Second, we could not obtain visual field data for all the patients because visual field acuity results for children are less reliable due to poor patient cooperation and because the follow-up time was not long enough. Third, the sample size is small. Fourth, the follow-up time is too short.

In conclusion, ocular hypertension and cataracts are the most common complications in children that have long-term oral steroid use. The highest incidence of ocular hypertension occurs in the first 6 months of steroid use, and the highest incidence of cataracts occurs after the first year. Regular IOP and slit-lamp examinations should be done in children with long-term steroid use. The incidence of cataract is higher in patients with ocular hypertension than in patients with normal IOP.

Authors’ contributions HY collected and performed the data analyses and wrote the manuscript. XT, JY and TL contributed significantly to analysis and manuscript preparation. WS, LL and CP contributed to the conception of the study and helped perform the analysis with constructive discussions.

Funding No funds, grants, or other support was received.

Availability of data and materials Data transparency.

Code availability Not applicable.

Declarations

Conflict of interest The authors have no financial or proprietary interests in any material discussed in this article.

Ethical approval Appropriate approvals have been approved.

Consent to participate Appropriate statements have been signed.

Consent for publication Appropriate statements have been approved.

References

1. Choi W, Bae HW, Choi EY et al (2020) Age as a risk factor for steroid-induced ocular hypertension in the non-paediatric population. Br J Ophthalmol 104(10):1423–1429. https://doi.org/10.1136/bjophthalmol-2019-314559
2. Ohji M, Kinoshita S, Ohmi E, Kuwayama Y (1991) Marked intraocular pressure response to instillation of corticosteroids in children. Am J Ophthalmol 112(4):450–454. https://doi.org/10.1016/s0002-9394(14)76256-7
3. Lam DS, Kwok AK, Chew S (1997) Accelerated ocular hypertensive response to topical steroids in children. Br J Ophthalmol 81(5):422–423. https://doi.org/10.1136/bjo.81.5.421d
4. Hutcheson KA (2007) Steroid-induced glaucoma in an infant. J AAPOS 11(5):522–523. https://doi.org/10.1016/j.jaapos.2007.03.008
5. Roberti G, Oddone F, Agnifili L et al (2020) Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol 65(4):458–472. https://doi.org/10.1016/j.survophthal.2020.01.002
6. James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23(5):403–20. https://doi.org/10.1089/jop.2006.0067
7. Black RL, Oglesby RB, Von Sallmann L, Bunim JJ (1960) Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 174:166–171. https://doi.org/10.1001/jama.1960.63030020005014
8. Kačmař J, Cholevěk D (2019) Corticosteroid induced posterior subcapsular cataract. Cesk Slov Oftalmol 74(6):226–232. https://doi.org/10.31348/2018/6/2
9. Morgan KS (1993) Cataract surgery and intraocular lens implantation in children. Curr Opin Ophthalmol 4(1):54–60. https://doi.org/10.1097/00055735-199302000-00010
10. Crews SJ (1963) Posterior subcapsular lens opacities in patients on long-term corticosteroid therapy. Br Med J 22:1644–1646
11. Ng JS, Fan DS, Young AL, Yip NK, Tam K, Kwok AK, Lam DS (2000) Ocular hypertensive response to topical dexamethasone in children: a dose-dependent phenomenon. Ophthalmology 107(11):2097–100. https://doi.org/10.1016/s0161-6420(00)00357-2

12. Biedner BZ, David R, Grudsky A, Sachs U (1980) Intraocular pressure response to corticosteroids in children. Br J Ophthalmol 64(6):430–431. https://doi.org/10.1016/s0161-6420(97)30052-9

13. Kwok AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO (1997) Ocular-hypertensive response to topical steroids in children. Ophthalmology 104(12):2112–2116. https://doi.org/10.1016/s0161-6420(97)30052-9

14. Tham CC, Ng JS, Li RT, Chik KW, Lam DS (2004) Intraocular pressure profile of a child on a systemic corticosteroid. Am J Ophthalmol 137(1):198–201. https://doi.org/10.1016/s0002-9394(03)00838-9

15. Tripathi RC, Kipp MA, Tripathi BJ, Kirschner BS, Borisuth NS, Shevell SK et al (1992) Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 3(3–4):469–482

16. Grossman BJ, Ozoo NF, De Benedetti C (1968) Intraocular pressure changes in children with the use of corticosteroid therapy. Proc Inst Med Chic 27(3):55–56

17. Kaur S, Dhiman I, Kaushik S, Raj S, Pandav SS (2016) Outcome of ocular steroid hypertensive response in children. J Glaucoma 25(4):343–347. https://doi.org/10.1097/IJG.0000000000000209

18. Armaly MF (1963) Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 70:482–491. https://doi.org/10.1001/archophthalmol.1963.00960050484010

19. Armaly MF (1963) Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 70:492–499. https://doi.org/10.1001/archophthalmol.1963.00960050494011

20. Cannahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11(6):478–483. https://doi.org/10.1097/00005573-200012000-00016

21. Prasad D, Poddar U, Kanaujia V, Yachha SK, Srivastava A (2019) Effect of long-term oral steroids on intraocular pressure in children with autoimmune hepatitis: a prospective cohort study. J Glaucoma 28(10):929–933. https://doi.org/10.1097/IJG.0000000000001352

22. Chen CH, Chen CM, Lee PP (1994) The effect of betamethasone on intraocular pressure in nephrotic children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 35(3):197–201

23. Feroze KB, Khazaeni L (2021) Steroid Induced Glaucoma. 2021 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.@@@

24. Kaye LD, Kalenak JW, Price RL, Cunningham R (1993) Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 30(3):142–144

25. Hayasaka Y, Hayasaka S, Matsuura H (2006) Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy. Ophthalmologica 220(3):181–185. https://doi.org/10.1159/000091762

26. Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS (2001) Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol 29(4):239–243. https://doi.org/10.1046/j.1442-9071.2001.00426.x

27. Loredo A, Rodriguez RS, Murillo L (1972) Cataracts after short-term corticosteroid treatment. N Engl J Med 286(3):160. https://doi.org/10.1056/NEJM197201202860317

28. Bachmann HJ, Schildberg P, Olbing H, Krämer D, Waubke T (1977) Cortisone cataract in children with nephrotic syndrome. Eur J Pediatr 124(4):277–283. https://doi.org/10.1007/BF00441935

29. Jobling AI, Augustyn RC (2002) What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Opt 85(2):61–75. https://doi.org/10.1111/j.1444-0938.2002.tb03011.x

30. Urban RC Jr, Cotlier E (1986) Corticosteroid-induced cataracts. Surv Ophthalmol 31(2):102–110. https://doi.org/10.1067/mso.1986.6257(86)90077-9

31. Williamson J, Paterson RW, McGavin DD, Jasani MK, Boyle JA, Doig WM (1969) Posterior subcapsular cataracts and glaucoma associated with long-term oral corticosteroid therapy. In patients with rheumatoid arthritis and related conditions. Br J Ophthalmol 53(6):361–72. https://doi.org/10.1136/bjo.53.6.361

32. Fini ME, Schwartz SG, Gao X, Jeong S, Patel N, Itakura T (2017) Steroid-induced ocular hypertension/glaucoma: focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res 56:58–83. https://doi.org/10.1016/j.preteyeres.2016.09.003

33. Kubo E, Shibata T, Singh DP, Sasaki H (2018) Roles of TGF beta and FGF signals in the lens: tropomyosin regulation for posterior capsule opacity. Int J Mol Sci. https://doi.org/10.3390/ijms19103093

34. Aksoy FE, Altan C, Yilmaz BS, Yilmaz I, Tunç U, Kesim C (2020) A comparative evaluation of segmental analysis of macular layers in patients with early glaucoma, ocular hypertension, and healthy eyes. J Fr Ophtalmol 43:869–878. https://doi.org/10.1016/j.jfo.2019.12.020

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.